ReviewFrontiers in immunology2021

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

Liyang Fei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.